SAN DIEGO, July 5, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 7th Annual JMP Securities Healthcare Conference on Thursday, July 12 at 10:30 a.m. Eastern Time in New York, NY, and provide a business overview and update.
A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of the presentation will be available at the same location for 90 days following the presentation.
About Optimer Pharmaceuticals Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD) and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.
Contacts Optimer Pharmaceuticals, Inc. David Walsey, VP of Investor Relations and Corporate Communications (858) 964-3418
Canale Communications Jason I. Spark, Senior Vice President 619-849-6005 Jason@canalecomm.com
OPTIMER and DIFICID are trademarks of Optimer Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.
SOURCE Optimer Pharmaceuticals, Inc.